ClinicalTrials.gg
RecruitingNCT06607458DEL-LIVERUpdated Oct 20, 2026

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

A Phase 2 interventional study of Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab and Trifluridine-tipiracil plus Bevacizumab Alone in Refractory Metastatic Colorectal Cancer, sponsored by Delcath Systems Inc.. Recruiting at 20 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Delcath Systems Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 20, 2026First site in United Kingdom7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
825th of 1,934
90 · median 64
Started
2025
with 143 others
Phase 2
511 of 2,342
66 open now
Primary completion
2026-12
later than 139 of 627 live
Registered
2,066th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 825th largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 144 that started in 2025, is one of 511 in phase 2, reaches primary completion later than 139 of the 627 other live ones, and was the 2,066th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.

Participants will:

  • Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone
  • Visit clinic at least every two weeks for checkups and tests
  • Complete scans approximately every two months
Read the detailed description

This is an open-label, randomized, multi-center study in which patients with liver dominant refractory mCRC will be randomized 2:1 to receive melphalan/HDS (2 cycles) followed by trifluridine-tipiracil plus bevacizumab treatment (Arm A) or trifluridine-tipiracil plus bevacizumab alone (Arm B).

Approximately 90 patients will be randomized 2:1 to the two treatment arms (Arm A, n=60; Arm B, n=30). Patients will receive one of the following treatments within 14 days of randomization:

  • Arm A: Patients will be treated with melphalan/HDS 3.0 mg/kg ideal body weight (IBW) for two treatment cycles. The second melphalan/HDS treatment will be administered 6 weeks after the first treatment with an acceptable delay of up to 2 weeks (8 weeks total) to allow for recovery of melphalan-related toxicity, if needed. Tumor response will be assessed prior to Cycle 2 of melphalan/HDS (6 to 8 weeks after Cycle 1 melphalan/HDS treatment), at the end of Week 16 (+/- 7 days), and every 8 weeks (+/- 7 days) thereafter during trifluridine-tipiracil plus bevacizumab treatment.
  • Arm B: Patients will be treated with standard regimen of trifluridine-tipiracil and bevacizumab.

In both treatment arms, treatment with trifluridine-tipiracil plus bevacizumab will continue until disease progression, death, intolerable adverse events, consent withdrawal, principal investigator decision, or termination of study by Sponsor.

Cross-over: There will be no cross-over between the two arms of the study. Efficacy and Safety Assessment: Evaluation of tumor response will be determined by the local principal investigator using RECIST 1.1 criteria. Tumor response evaluation and patient management will be according to the principal investigator assessment of images and patients' clinical needs. Patients with progressive disease (PD) will be discontinued from study treatment and will be followed for survival until withdrawal of consent or death.

Study treatment will be discontinued if recovery from treatment related toxicity requires more than 2 weeks from the end of the treatment cycle during melphalan/HDS cycles (Arm A only), or more than a 28-day delay in the start of the next cycle of trifluridine-tipiracil plus bevacizumab; the end of treatment (EOT) visit will be conducted at that time or within 4 weeks.

Safety will be monitored continuously by documentation of AEs, SAEs, clinical laboratory measurements, vital signs, and physical examination.

Data Safety Monitoring Board (DSMB): A DSMB including independent (non-investigator) clinicians will oversee the emerging patient safety profile during the study. The DSMB will review study data on a regular basis according to the DSMB Charter.

03

Conditions studied

  • Refractory Metastatic Colorectal Cancer

Keywords

  • melphalan/HDS
  • melphalan/hepatic delivery system
  • trifluridine-tipiracil
  • trifluridine-tipiracil (FTD-TPI)
  • trifluridine-tipiracil (FTD-TPI) plus bevacizumab
  • trifluridine-tipiracil plus bevacizumab
  • hepatic delivery system
  • melphalan
  • liver dominant disease
  • colorectal cancer
  • metastatic colorectal cancer
  • refractory metastatic colorectal cancer
  • rectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of colorectal cancer and histologically or cytologically proven CRC metastases that occupy 50% or less of the liver parenchyma.
  • Patient has liver-dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and the liver lesions are not resectable or treatable with ablation or are associated with extrahepatic disease that makes surgical intervention non-curative.
  • Disease in the liver must be measurable (per v.1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI).
  • If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: up to 5 tumor lesions in the lung with longest diameter not greater than 2 cm and/or up to 5 lymph nodes that measure 2 cm or less per lesion; solitary lesions definitively treated with no sign of progression in the last 6 months.
  • Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization.
  • Previous treatment and progressed on or following, or intolerant to, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and/or an anti-EGFR therapy if RAS wild-type.
  • PS of 0-1 within 14 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Class B or C cirrhosis or evidence of portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).
  • functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.
  • History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.
  • History of bleeding disorders, presence of , or other intracranial abnormalities found on baseline radiologic imaging that would put them at risk for bleeding with anti-coagulation.
  • Known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.
  • Active second , or has history of recently definitively treated invasive cancer in the past 2 years prior to enrolment with the exception of non-melanoma skin cancer.
  • Peritoneal lesions or large abdominal masses.
  • Use of drugs.
  • Inability to temporarily stop chronic anti-coagulation therapy.
  • Active bacterial infections with systemic manifestations.
  • Active viral infection, including and infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).
  • Severe allergic reaction to iodine contrast that cannot be controlled by premedication with antihistamines and .
  • History of or known to melphalan or the components of the melphalan/HDS system.
  • History of known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.
  • Uncontrolled endocrine disorder including diabetes mellitus, hypothyroidism, or hyperthyroidism.
  • Received anti-cancer therapy including radiotherapy or agent for any indication ≤ 30 days prior to randomization
  • Previous treatment with trifluridine-tipiracil.
  • History of allergic reactions attributed to compounds of similar composition to trifluridine/tipiracil or any of its .
  • Hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.
  • History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.
  • History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
  • to bevacizumab, including uncontrolled hypertension, history of active fistula or bowel perforation (unless in the setting of a resected primary), history of CVA or arterial thrombotic event in the last 1 year, or history of venous thrombotic event in the last 30 days.
  • Evidence of hepatic vein or portal vein thrombosis
  • Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Melphalan/HDS followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab

    Melphalan/HDS is given as an infusion of Melphalan into the hepatic artery under general anesthesia. This treatment is administered twice, 8 weeks apart. Following 2 treatments with Melphalan/HDS, Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity

    Drug: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab

  • Active comparator
    Trifluridine-tipiracil plus Bevacizumab Alone

    Trifluridine-tipiracil plus Bevacizumab is the standard of care for patients with metastatic colorectal cancer. Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity

    Drug: Trifluridine-tipiracil plus Bevacizumab Alone

Interventions

  • DrugMelphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab

    Drug page: MelphalanStudies of MelphalanMelphalan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trifluridine-tipiracil plus Bevacizumab Alone

    Also known as: Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil, Melphalan/HDS

  • DrugTrifluridine-tipiracil plus Bevacizumab Alone

    Drug page: BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trifluridine-tipiracil plus Bevacizumab Alone

    Also known as: Trifluridine-tipiracil, Bevacizumab

06

What researchers measure

Primary outcomes

  1. hPFS

    Hepatic Progression Free Survival

    Time frame: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months

Secondary outcomes

  1. PFS

    Progression Free Survival

    Time frame: time from randomization to the first occurrence of progression, assessed up to 24 months

  2. OS

    Overall Survival

    Time frame: time from randomization date to the date of death due to any cause, assessed up to 36 months

  3. ORR

    Overall Response Rate complete response \[CR\] + partial response \[PR\]

    Time frame: Baseline through completion of treatment, assessed up to 24 months

  4. hORR

    Hepatic Overall Response Rate

    Time frame: assessed from Baseline until there is evidence of disease progression in the liver, assessed up to 24 months

  5. DOR

    Duration of Response

    Time frame: assessed from Baseline until there is evidence of disease progression, assessed up to 24 months

  6. DCR

    Disease Control Rate

    Time frame: complete response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months

  7. hDOR

    Hepatic Duration of Response

    Time frame: assessed from Baseline until there is evidence of hepatic disease progression, assessed up to 24 months

  8. hDCR

    Hepatic Disease Control Rate

    Time frame: complete hepatic response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months

Other outcomes

  1. Safety and Tolerability

    Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Changes from baseline in physical examination findings, vital signs, clinical laboratory parameters, electrocardiogram (ECG) and echocardiogram (ECHO) parameters

    Time frame: assessed from signed informed consent form until study completion

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Delcath does not currently have a plan to share IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 16 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2024
First posted
Sep 23, 2024
StartActual
Aug 5, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Oct 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed — first site in United Kingdom
Show 7 added (4 United States, 1 Germany, 1 Turkey (Türkiye), 1 United Kingdom)
  • Sylvester Comprehensive Cancer Center, University of Miami Hospital · Miami, United States
  • Northwestern University - Feinberg School of Medicine · Chicago, United States
  • The University of Kansas Clinical Research Center · Overland Park, United States
  • University of North Carolina · Chapel Hill, United States
  • Asklepios Klinik Altona · Hamburg, Germany
  • Ulus Liv Hospital · Istanbul, Turkey (Türkiye)
  • Southampton General Hospital · Southampton, United Kingdom
Show 1 removed
  • The University of Kansas Clinical Research Center · Fairway, United States
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    7 sites added, 1 site removed — first site in United Kingdom
    Show 7 added (4 United States, 1 Germany, 1 Turkey (Türkiye), 1 United Kingdom)
    • Sylvester Comprehensive Cancer Center, University of Miami Hospital · Miami, United States
    • Northwestern University - Feinberg School of Medicine · Chicago, United States
    • The University of Kansas Clinical Research Center · Overland Park, United States
    • University of North Carolina · Chapel Hill, United States
    • Asklepios Klinik Altona · Hamburg, Germany
    • Ulus Liv Hospital · Istanbul, Turkey (Türkiye)
    • Southampton General Hospital · Southampton, United Kingdom
    Show 1 removed
    • The University of Kansas Clinical Research Center · Fairway, United States
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06607458
Lead sponsor
Delcath Systems Inc.
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Aug 5, 2025
Primary completion
Dec 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Matthew Cooney, MD
Contact
MedicalMonitoring@delcath.com
216-374-8221
Marwan Fakih, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melphalan

Start the discussion